^
    Back
    Association details:
    Biomarker:ERBB3 mutation + HER-2 mutation
    Cancer:Solid Tumor
    Drug Class:HER2 inhibitor
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: D – Preclinical
    Source:
    Cancer Cell
    Title:

    Co-occurring gain-of-function mutations in HER2 and HER3 modulate HER2/HER3 activation, oncogenesis, and HER2 inhibitor sensitivity

    Published date:
    06/24/2021
    Excerpt:
    Co-expression of mutant HER2/HER3 enhances HER2/HER3 co-immunoprecipitation and ligand-independent activation of HER2/HER3 and PI3K/AKT, resulting in enhanced growth, invasiveness, and resistance to HER2-targeted therapies, which can be reversed by combined treatment with PI3Kα inhibitors.
    DOI:
    10.1016/j.ccell.2021.06.001